Clinical Trial Update: Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy [Phase 1]

View source ↗

Summary

Phase 1 trial report updates immune responses to antigen-bearing dendritic cell therapy in patients with melanoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dendritic cell vaccine (antigen-bearing)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Melanoma | Phase 1 | Status: COMPLETED